Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
• Targeted therapies inhibiting EGFR are being developed for various cancers, including non-small-cell lung cancer (NSCLC).
• Compounds like ZD1839, IMC-C225, and OSI-774 are leading EGFR inhibitors in clinical development.

Purpose of the Study:

• To review preclinical and clinical data on EGFR inhibitors for locally advanced NSCLC.
• To explore the potential of EGFR inhibitors as adjuncts to standard chemoradiation therapy for Stage III NSCLC.
• To provide an overview of ongoing and proposed clinical trials investigating EGFR inhibitors in Stage III NSCLC.

Main Methods:

• Review of preclinical studies on EGFR inhibitors' radiosensitizing and cytotoxic effects.
• Analysis of clinical trial data for EGFR inhibitors in NSCLC.
• Compilation of information on ongoing and proposed clinical trials for Stage III NSCLC.

Main Results:

• Preclinical data suggest EGFR inhibitors enhance radiation sensitivity and chemotherapy efficacy.
• Clinical studies support the role of EGFR inhibitors alone or in combination for NSCLC.
• Several clinical trials are investigating the addition of EGFR inhibitors to standard therapy for Stage III NSCLC.

Conclusions:

• EGFR inhibitors represent a promising targeted therapy for NSCLC.
• Combining EGFR inhibitors with chemotherapy and radiation may improve outcomes for Stage III NSCLC.
• Ongoing clinical trials will clarify the role of EGFR inhibitors in the combined-modality treatment of locally advanced NSCLC.